To evaluate whether the CLDN4 signaling drives breast cancer metabolism and progression via LXRβ, we generated T47D:CLDN4–/–:LXRβ–/– (hereafter designated as "T47D:dKO"), T47D:dKO:CLDN4, and T47D:dKO:CLDN4:LXRβ cells (Fig. 5A, B; Additional file 1: Fig. S2B). Here, NR1H2 is linked to breast carcinoma.